Biotechnology Companies Face New Regulatory and Commercial Challenges. When Should They Bring in Outside Counsel?
Biotechnology companies face important legal and commercial decisions as they develop new therapies, negotiate partnerships, and expand into international markets. We examine when outside counsel can help companies address U.S. regulatory requirements, pharmaceutical licensing, reimbursement, commercial agreements, and cross-border business arrangements.
Healthcare Advocacy Across the Northeast
Lanton Strategies represents healthcare providers, hospitals, health systems, biotechnology companies, pharmaceutical manufacturers and industry associations before state legislatures and regulatory agencies across the Northeast. Learn how our government affairs services help organizations address legislation, rulemaking and policies affecting their businesses.
When a Drug Launch Moves, the Business Changes Too
Roche's changing European plans raise questions about drug pricing, reimbursement and launch timing. Ron Lanton examines what these decisions mean for biotechnology companies and investors, following recent reporting by Maggie Fick in Endpoints News.
https://endpoints.news/roches-changing-plans-show-how-mfn-is-complicating-european-drug-launches/
COINS and Biotech: The Deal Structure May Matter More Than the License
Treasury’s proposed COINS rules may leave traditional pharma licensing outside core restrictions while creating new questions for equity, joint-venture and NewCo deals.
Massachusetts Healthcare & Life Sciences Real Estate From Scarcity to Selectivity: A Market Reset Creates a New Set of Opportunities
Massachusetts’ life sciences real estate market is changing, creating new opportunities for healthcare and biotech companies evaluating laboratory space, expansion and long-term facilities. This white paper examines how shifting market conditions, lease negotiations, regulatory requirements and capital considerations are reshaping commercial real estate decisions across Greater Boston and Cambridge.